<DOC>
	<DOCNO>NCT01308567</DOCNO>
	<brief_summary>Primary Objective : - To demonstrate superiority cabazitaxel plus prednisone 25 mg/m^2 ( Arm A ) 20 mg/m^2 ( Arm B ) versus docetaxel plus prednisone ( Arm C ) term overall survival ( OS ) participant metastatic castration resistant prostate cancer ( mCRPC ) previously treat chemotherapy . Secondary Objectives : - To evaluate safety 3 treatment arm . - To compare efficacy cabazitaxel 20 mg/m^2 25 mg/m^2 docetaxel : - Progression Free Survival ( PFS ) ( RECIST 1.1 ) - Tumor progression free survival ( RECIST 1.1 ) - Tumor response participant measurable disease ( RECIST 1.1 ) , - PSA response - PSA-Progression free survival ( PSA-PFS ) . - Pain response participant stable pain baseline - Pain progression free survival - Time occurrence skeletal related event ( SRE ) - To compare Health-Related Quality Life ( HRQL ) . - To assess pharmacokinetics pharmacogenomics cabazitaxel .</brief_summary>
	<brief_title>Cabazitaxel Versus Docetaxel Both With Prednisone Patients With Metastatic Castration Resistant Prostate Cancer</brief_title>
	<detailed_description>Participants treat progressive disease , unacceptable toxicity , participant 's refusal study treatment . All participant follow study treatment completion study treatment follow period death study cutoff date , whichever come first .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Inclusion criterion : I 01 . Histologically cytologicallyconfirmed prostate adenocarcinoma . I 02 . Metastatic disease . I 03 . Progressive disease receive hormonal therapy surgical castration . I 04 . Effective castration ( serum testosterone level â‰¤0.50 ng/mL ) orchiectomy and/or luteinizing hormonereleasing hormone ( LHRH ) agonists antagonist without antiandrogens . Exclusion criterion : E 01 . Prior chemotherapy prostate cancer , E 02 . Less 28 day elapse prior treatment estramustine , radiotherapy surgery time randomization . Participants biphosphonates prior study entry . E 03 . Prior isotope therapy , whole pelvic radiotherapy , radiotherapy &gt; 30 % bone marrow . E 04 . Adverse event ( exclude alopecia list specific exclusion criterion ) prior anticancer therapy grade &gt; 1 ( National Cancer Institute Common Terminology Criteria [ NCI CTCAE ] v4.03 ) time randomization . E 05 . Less 18 year ( country 's legal age majority legal age &gt; 18 year ) . E 06 . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 . E 07 . History brain metastasis , uncontrolled spinal cord compression , carcinomatous meningitis new evidence brain leptomeningeal disease . E 08 . Prior malignancy . E 09 . Participation another clinical trial concurrent treatment investigational drug within 30 day prior randomization . E 10 . Any follow within 6 month prior study enrollment : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , New York Heart Association ( NYHA ) class III IV congestive heart failure , stroke transient ischemic attack . E 11 . Any follow within 3 month prior randomization : treatment resistant peptic ulcer disease , erosive esophagitis gastritis , infectious inflammatory bowel disease , diverticulitis , pulmonary embolism , uncontrolled thromboembolic event . E 12 . Acquired immunodeficiency syndrome ( AIDSrelated illness ) know HIV disease require antiretroviral treatment . E 13 . Any severe acute chronic medical condition could impair ability participant participate study interfere interpretation study result , participant unable comply study procedure . E 14 . Absence sign dated Institutional Review Board ( IRB ) approve participant informed consent form prior enrollment study . E 15 . Participants reproductive potential agree use accept effective method contraception study treatment period . E 16 . History hypersensitivity docetaxel , polysorbate 80 . E 17 . Inadequate organ bone marrow function E 18 . Contraindications use corticosteroid treatment . E 19 . Symptomatic peripheral neuropathy grade &gt; 2 ( National Cancer Institute Common Terminology Criteria [ NCI CTCAE ] v.4.03 ) . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>